Endocannabinoids - Open Access .click

Results 121 to 130 of about 32,682 (238)

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, Volume 183, Issue 16, Page 4715-4734, August 2026.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli +8 more
wiley +1 more source

Inhibition of peripheral CB1 receptors modulates food intake and metabolic efficiency in obesity independently of the gut–brain vagal axis

British Journal of Pharmacology, Volume 183, Issue 16, Page 4953-4968, August 2026.
Background and Purpose Obesity involves profound disruptions in neuronal circuits, neuroendocrine communication and the endocannabinoid system. While global blockade of cannabinoid CB1 receptors improves metabolism, its clinical use is limited by neuropsychiatric side effects.
Oriane Onimus +7 more
wiley +1 more source

Endocannabinoids and non-alcoholic steatohepatitis

The Saudi Journal of Gastroenterology, 2006
Non alcoholic steatohepatitis (NASH) has gained a lot of attention recently due to the increased prevalence of diabetes, obesity, and hyperlipedemia. The endogenous compounds, endocannabinoids (ECBs), bind to the same receptors as tetrahydrocannabinol ...
Helmy Ahmed
doaj

MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future.

European Journal of Endocrinology, 2017
Vincent Simon, D. Cota
semanticscholar +1 more source

Endocannabinoids [PDF]